In femoro-popliteal disease, paclitaxel-coated balloon (PCB) improved angiographic outcomes as compared with uncoated balloon (UCB) angioplasty. Nevertheless, clinical efficacy of PCB remained uncertain. The aim of the study is to evaluete the angiographic and clinical efficacy of PCB in comparison with UCB in an meta-anallisys.
Inclusion criteria were randomized design intention to treat analysis ≥6-month follow-up. Exclusion criteria were other vessel treated than FPA, other device used than PCB or UCB, irretrievable or duplicated data. Primary endpoint was 6-month angiographic late lumen loss (LLL). Secondary endpoints were: angiographic restenosis, target lesion revascularization (TLR) and mortality, as per protocol defined.
Results: A total of 381 patients (4 trials) were included. Median follow-up was 10.3 months. Angioplasty with PCB was superior to UCB in terms of TLR and angiographic restenosis.
The PCB angioplasty is associated with better clinical and angiographic outcomes in comparison with the UCB angioplasty.
«
In femoro-popliteal disease, paclitaxel-coated balloon (PCB) improved angiographic outcomes as compared with uncoated balloon (UCB) angioplasty. Nevertheless, clinical efficacy of PCB remained uncertain. The aim of the study is to evaluete the angiographic and clinical efficacy of PCB in comparison with UCB in an meta-anallisys.
Inclusion criteria were randomized design intention to treat analysis ≥6-month follow-up. Exclusion criteria were other vessel treated than FPA, other device used than...
»